Search | IOVS | ARVO Journals

Showing 1 – 20 of 45

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2025

Efficacy and Safety of Brolucizumab in Proliferative Diabetic Retinopathy: 2-Year Results from the CONDOR Study

Yongsoo Kim; Youxin Chen; Xiaorong Li; Masahiko Shimura; Taiji Sakamoto; Andres Emanuelli; Hani Salehi; Kang Yan; Lidija Kovacic; Sebastian Wolf; Charles Clifton Wykoff

Invest. Ophthalmol. Vis. Sci.. 2025; 66(8):4759.

Eye Movements, Strabismus, Amblyopia and Neuro-ophthalmology June 2025

Biallelic NSUN3 Variants Cause Diverse Phenotypic Spectrum Disease: From Isolated Optic Atrophy to Severe Early-Onset Mitochondrial Disorder

PDF

Neringa Jurkute; Heiko Brennenstuhl; Monika Kustermann; Lindsey Van Haute; Christian D. Mutti; Enrico Bugiardini; Takayuki Handa; Masaru Shimura; Axel Petzold; James Acheson; Anthony G. Robson; William L. Macken; Michael G. Hanna; Robert D. S. Pitceathly; Ashirwad Merve; Urania Kotzaeridou; Stefan Kölker; Michael Freilinger; Marcus Erdler; Reginald E. Bittner; Johannes A. Mayr; Yasushi Okazaki; Kei Murayama; Holger Prokisch; Andrew R. Webster; Michal Minczuk; Gavin Arno; Berthold Pemp; Georg F. Hoffmann; Wolfgang M. Schmidt; Patrick Yu-Wai-Man
TAGS: family, mitochondrial diseases, optic atrophy, phenotype, mitochondria, optic nerve disorders, respiratory chain
Invest. Ophthalmol. Vis. Sci.. 2025; 66(6):17. https://doi.org/10.1167/iovs.66.6.17

Includes: Supplemental Content

Retina December 2024

Changes in Aqueous Angiopoietin-1/2 Concentrations During the Induction Phase of Intravitreal Faricimab Injections for Diabetic Macular Edema

PDF

Masahiko Shimura; Shotaro Sasaki; Ryota Nonaka; Ikumi Kashiwagi; Kanako Yasuda; Hidetaka Noma; Hitoshi Takagi
TAGS: angiopoietins, cytokine, diabetic macular edema, faricimab, injections, vascular endothelial growth factor a
Trans. Vis. Sci. Tech.. 2024; 13(12):35. https://doi.org/10.1167/tvst.13.12.35

ARVO Annual Meeting Abstract June 2024

Brolucizumab for the treatment of proliferative diabetic retinopathy (PDR): 54-week results from the CONDOR study

Yongsoo Kim; Charles Clifton Wykoff; Andres Emanuelli; Youxin Chen; Xiaorong Li; Yanping Song; Xiaoling Liu; Masahiko Shimura; Kang Yan; Chang Liu; Li Zhu; Lidija Kovacic

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):3206.

ARVO Annual Meeting Abstract June 2024

Flare levels after intravitreal injection of brolucizumab for diabetic macular edema

Yutaka Yamada; Yushi Ichihashi; yoshihiro takamura; Takao Hirano; Masahiko Shimura; Keisuke Yoneda; Keiichiro Konno; Masaru Inatani

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6214.

ARVO Annual Meeting Abstract June 2024

Changes in Aqueous Angiopoietin Concentrations during the Induction Phase of Intravitreal Faricimab Injections for Diabetic Macular Edema

Masahiko Shimura; Shotaro Sasaki; Ryota Nonaka; Kanako Yasuda; Hidetaka Noma

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):6212.

ARVO Annual Meeting Abstract June 2023

Real-world management of treatment-naïve diabetic macular edema after the approval of anti-VEGF therapy in Japan: 2-year visual outcome focusing on the starting year of intervention from STREAT-DME 2 study

Masahiko Shimura; Shigehiko Kitano; Taiji Sakamoto

Invest. Ophthalmol. Vis. Sci.. 2023; 64(8):2640.

ARVO Annual Meeting Abstract July 2019

Real world management of treatment-naïve diabetic macular edema: visual outcome based on the starting year of intervention

Ryosuke Motohashi; Masahiko Shimura; Shigehiko Kitano; Taiji Sakamoto

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2603.

ARVO Annual Meeting Abstract July 2019

Real world data of management of treatment-naïve diabetic macular edema in JAPAN: Two years visual outcome with and without anti-VEGF therapy

Daisuke Muramatsu; Masahiko Shimura; Shigehiko Kitano; Taiji Sakamoto

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):2641.

ARVO Annual Meeting Abstract July 2019

Change of Cytokines in Recurred Patients After Ranibizumab Therapy for Branch Retinal Vein Occlusion With Macular Edema

Hidetaka Noma; Kanako Yasuda; Masahiko Shimura

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4088.

ARVO Annual Meeting Abstract July 2018

Dynamics of inflammatory factors in aqueous humor under Ranibizumab or Aflibercept treatment for age-related macular degeneration

Ryosuke Motohashi; Hidetaka Noma; Kanako Yasuda; Osamu Kotake; Hiroshi Goto; Masahiko Shimura

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):62.

ARVO Annual Meeting Abstract July 2018

Anti-vascular endothelial growth factor agents reduce inflammation in central retinal vein occlusion with macular edema

Hidetaka Noma; Kanako Yasuda; Masahiko Shimura

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):389.

ARVO Annual Meeting Abstract July 2018

Survey of TREATment for Diabetic Macular Edema (STREAT-DME) Study: Results by year from real world data in Japan

TAKUYA UTSUMI; Masahiko Shimura; Shigehiko Kitano; Taiji Sakamoto

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1057.

ARVO Annual Meeting Abstract July 2018

Survey of TREATment for Diabetic Macular Edema (STREAT-DME) Study: Results by treatment options from real world data in Japan

Daisuke Muramatsu; Masahiko Shimura; Shigehiko Kitano; Taiji Sakamoto

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1895.

ARVO Annual Meeting Abstract July 2018

Real-World Evidence Based on the Results of a Multicenter Study in Japan of Surgical Procedures for Young Japanese Patients with Rhegmatogenous Retinal Detachment

Ingen Shu; Hiroto Ishikawa; Hiroki Nishikawa; Shohei Morikawa; Taiji Sakamoto; Mineo Kondo; Norimasa Iwasaki; Toshi Toibana; Yoshihiro Takamura; Masahiko Shimura; Yutaka Sakurai; Fumi Gomi

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4233.

ARVO Annual Meeting Abstract July 2018

Preoperative OCT images in macular-off rhegmatogenous retinal detachment

Kazuhiko Umazume; Yoshihiko Usui; Yoshihiro Wakabayashi; Masahiko Shimura; Hiroshi Goto

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4235.

ARVO Annual Meeting Abstract June 2017

MCP-1 disrupts morphologic and functional barrier properties of polarized retinal pigment epithelium

Hidetaka Noma; Kevin McDonald; Masahiko Shimura; Shigeo Tamiya

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):598.

ARVO Annual Meeting Abstract September 2016

Vitreous concentrations of VEGF family indicate visual prognosis after vitrectomy in patients with rhegmatogenous retinal detachment

Masahiko Shimura; Ryosuke Motohashi; Kanako Yasuda; Hidetaka Noma

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):1028.

ARVO Annual Meeting Abstract September 2016

Role of Soluble Vascular Endothelial Growth Factor Receptor Signaling and Other Factors or Cytokines in Diabetic Macular Edema

Hidetaka Noma; Kanako Yasuda; Masahiko Shimura

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):3245.

ARVO Annual Meeting Abstract June 2015

Change of Cytokines in Recurred Patients After Injection of Intravitreal Ranibizumab for Branch Retinal Vein Occlusion With Macular Edema

Hidetaka Noma; Kanako Yasuda; Hayate Nakagawa; Ryosuke Motohashi; Osamu Kotake; Hiroshi Goto; Masahiko Shimura

Invest. Ophthalmol. Vis. Sci.. 2015; 56(7 ):383.

1 2 3

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Efficacy and Safety of Brolucizumab in Proliferative Diabetic Retinopathy: 2-Year Results from the CONDOR Study

Biallelic NSUN3 Variants Cause Diverse Phenotypic Spectrum Disease: From Isolated Optic Atrophy to Severe Early-Onset Mitochondrial Disorder

Changes in Aqueous Angiopoietin-1/2 Concentrations During the Induction Phase of Intravitreal Faricimab Injections for Diabetic Macular Edema

Brolucizumab for the treatment of proliferative diabetic retinopathy (PDR): 54-week results from the CONDOR study

Flare levels after intravitreal injection of brolucizumab for diabetic macular edema

Changes in Aqueous Angiopoietin Concentrations during the Induction Phase of Intravitreal Faricimab Injections for Diabetic Macular Edema

Real-world management of treatment-naïve diabetic macular edema after the approval of anti-VEGF therapy in Japan: 2-year visual outcome focusing on the starting year of intervention from STREAT-DME 2 study

Real world management of treatment-naïve diabetic macular edema: visual outcome based on the starting year of intervention

Real world data of management of treatment-naïve diabetic macular edema in JAPAN: Two years visual outcome with and without anti-VEGF therapy

Change of Cytokines in Recurred Patients After Ranibizumab Therapy for Branch Retinal Vein Occlusion With Macular Edema

Dynamics of inflammatory factors in aqueous humor under Ranibizumab or Aflibercept treatment for age-related macular degeneration

Anti-vascular endothelial growth factor agents reduce inflammation in central retinal vein occlusion with macular edema

Survey of TREATment for Diabetic Macular Edema (STREAT-DME) Study: Results by year from real world data in Japan

Survey of TREATment for Diabetic Macular Edema (STREAT-DME) Study: Results by treatment options from real world data in Japan

Real-World Evidence Based on the Results of a Multicenter Study in Japan of Surgical Procedures for Young Japanese Patients with Rhegmatogenous Retinal Detachment

Preoperative OCT images in macular-off rhegmatogenous retinal detachment

MCP-1 disrupts morphologic and functional barrier properties of polarized retinal pigment epithelium

Vitreous concentrations of VEGF family indicate visual prognosis after vitrectomy in patients with rhegmatogenous retinal detachment

Role of Soluble Vascular Endothelial Growth Factor Receptor Signaling and Other Factors or Cytokines in Diabetic Macular Edema

Change of Cytokines in Recurred Patients After Injection of Intravitreal Ranibizumab for Branch Retinal Vein Occlusion With Macular Edema

To View More...

You must be signed into an individual account to use this feature.